Blockchain Registration Transaction Record

Cognition Therapeutics Drug Shows Encouraging Results in Phase 2 Trial

Cognition Therapeutics Inc. announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat dementia with Lewy bodies, showing potential breakthrough in treatment.

This news matters as it highlights a potential breakthrough in the treatment of dementia with Lewy bodies, a progressive form of dementia impacting about 1.4 million people in the U.S. With the promising results of CT1812, there is hope for a once-daily pill that can treat these devastating neurodegenerative conditions, which currently have few therapeutic options.